Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema.

Trial Profile

Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Ranibizumab (Primary) ; Triamcinolone (Primary)
  • Indications Diabetes mellitus; Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms LRT for DME
  • Most Recent Events

    • 07 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Dec 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 09 Dec 2011 Primary endpoint identified (optical coherence tomography outcomes) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top